<DOC>
	<DOCNO>NCT01584232</DOCNO>
	<brief_summary>The purpose trial examine efficacy safety once-weekly LY2189265 ( dulaglutide ) participant type 2 diabetes mellitus take oral antihyperglycemic medication ( OAM ) .</brief_summary>
	<brief_title>A Study Dulaglutide Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Rescue therapy ( defined alternative antihyperglycemic medication use dose modification oral antihyperglycemic medication [ OAM ] ) may initiate planned treatment period participant discontinue study drug meet prespecified threshold severe , persistent hyperglycemia . Efficacy data , well data hypoglycemic episode participant permanently discontinue study treatment switch another diabetes medication remain study , censor point initiate new treatment onwards .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Participants diagnosis type 2 diabetes mellitus least 6 month screen Participants take sulfonylurea ( glibenclamide , gliclazide , glimepiride ) and/or biguanide ( metformin buformin ) . The dose drug ( ) 8 week screen must stable Participants qualify glycosylated hemoglobin ( HbA1c ) value 7.0 % 10.0 % screen Participants body mass index ( BMI ) 18.5 35.0 kilogram per meter square ( kg/m^2 ) Participants diagnosis type 1 diabetes Participants previously treat glucagonlike peptide 1 ( GLP1 ) analog Participants receive therapy alphaglucosidase inhibitor ( aGI ) , thiazolidinedione ( TZD ) , glinide , dipeptidyl peptidaseIV ( DPPIV ) inhibitor within 3 month screen Participants currently take insulin previous insulin treatment within 3 month screen Participants obvious clinical sign symptom pancreatitis , history chronic pancreatitis , acute pancreatitis screening , determine investigator . Participants serum amylase concentration ≥ 3 time upper limit reference range and/or serum lipase concentration ≥ 2 time upper limit reference range , determined central laboratory screen Participants self family history medullary Ccell hyperplasia , focal hyperplasia , medullary thyroid carcinoma ( MTC )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Glucagon-like peptide-1 ( GLP-1 )</keyword>
</DOC>